Skip to main content

Table 2 Paired recipients who received graft donations from the same donors stratified by MSC

From: Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial

Recipient characteristics (paired)

Trials

Control

P value

Age (years)

40.8 ± 9.2

47.1 ± 10.2

0.60

Sex

 Male

14

11

0.53

 Female

7

10

Preoperative Cr (μmol/L)

1106.4 ± 326.9

967.3 ± 236.0

0.28

Previous transplants

 First transplant

20

21

1

 Second transplant

1

0

HLA mismatches

 Level 1

11

9

0.76

 Level 2

10

12

Pre-emptive dialysis vintage (years)

2.4 ± 2.2

2.1 ± 1.6

1

Cold ischemia time (h)

 < 6

14

13

1

 6–12

7

8

Postoperative complications

 DGF

2

7

0.13

 AR

3

1

0.61

 Complicated urinary tract infection

1

1

1

 Severe pneumonia

2

5

0.41

 Severe bleeding

0

0

1

 Renal allograft resection or embolism

1

1

1

 Other

1

1

1

  1. MSC mesenchymal stem cell, Cr creatinine, HLA human leukocyte antigen, DGF delayed graft function, AR acute rejection